Drug Landscape ›
Pegylated Interferon-alpha2a ›
Regulatory · United States
Marketing authorisation
FDA
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
Window: 20 April 2025 – 20 April 2026
Total reports: 5
Most-reported reactions
Anaemia — 1 report (20%) Condition Aggravated — 1 report (20%) Fatigue — 1 report (20%) Influenza Like Illness — 1 report (20%) Neuropathy Peripheral — 1 report (20%)
Source database →
Pegylated Interferon-alpha2a in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Frequently asked questions
Is Pegylated Interferon-alpha2a approved in United States?
Yes. FDA has authorised it.
Who is the marketing authorisation holder for Pegylated Interferon-alpha2a in United States?
Seoul National University Hospital is the originator. The local marketing authorisation holder may differ — check the official source linked above.